Date: 2017-11-14
Type of information: Collaboration agreement
Compound: LISA TRACKER kits for monitoring Flixabi® (an infliximab biosimilar)
Company: Theradiag (France) Biogen (USA - MA)
Therapeutic area:
Type agreement: collaboration
Action mechanism: theranostic test
Disease:
Details:
- • On November 14, 2017, Theradiag announced that it has entered into a partnership agreement with Biogen to provide its LISA TRACKER kits for monitoring Flixabi® (an infliximab biosimilar).
- Since 2016, Biogen has marketed in France two biosimilar drugs including Flixabi®, contributing to efforts to keep healthcare costs under control. As a result, Biogen will now be able to supply LISA TRACKER monitoring kits in the competitive tenders in which it participates in France and other European countries to optimize the treatment of patients receiving Flixabi®.
- Under this agreement, Theradiag will be Biogen’s preferred supplier of infliximab monitoring kits. Theradiag will also handle implementation, provide training to laboratories in how to use kits and follow up on clinician requests concerning monitoring. Biogen has previously validated the use of LISA TRACKER kits for monitoring Flixabi®.
Financial terms:
Latest news:
Is general: Yes
